TY - JOUR T1 - Interpreting the Jupiter trial: Statins can prevent VTE, but more study is needed JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 191 LP - 194 DO - 10.3949/ccjm.77a.09077 VL - 77 IS - 3 AU - Alejandro Perez AU - John R. Bartholomew Y1 - 2010/03/01 UR - http://www.ccjm.org/content/77/3/191.abstract N2 - Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE. ER -